Atossa Genetics (NASDAQ:ATOS) Announces Quarterly Earnings Results

Atossa Genetics (NASDAQ:ATOS) posted its quarterly earnings data on Tuesday. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.30, FiscalAI reports.

Atossa Genetics Stock Performance

ATOS traded up $0.08 during trading hours on Tuesday, reaching $2.21. The company’s stock had a trading volume of 33,313 shares, compared to its average volume of 112,657. Atossa Genetics has a 52 week low of $1.70 and a 52 week high of $14.85. The company’s 50-day moving average is $2.37 and its 200-day moving average is $3.78. The firm has a market cap of $22.07 million, a PE ratio of -0.71 and a beta of 1.38.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Wall Street Zen upgraded shares of Atossa Genetics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Atossa Genetics in a report on Tuesday, September 8th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $20.33.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other breast-related conditions. The company’s research is centered on targeted treatments intended to address unmet needs in the prevention and treatment of breast cancer.

Atossa’s lead program is (Z)-endoxifen, an oral selective estrogen receptor modulator being investigated primarily for estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.